

## INDEX

- ABORTION, SPONTANEOUS**  
effect of maternal smoking on risk, 158
- ACIDS**  
carcinogenicity, 38  
cocarcinogenicity, 38
- ACROLEIN**  
cocarcinogenicity, 94
- ADOLESCENTS**  
percent distribution of smokers by tar yield, 220-222  
role of lower tar and nicotine cigarettes in initiation of smoking habit, 183  
use of lower tar and nicotine cigarettes in males vs. females, 183  
use of lower tar cigarettes, 220-222
- ADRENAL CORTEX HORMONES**  
effect of nicotine on cortisol secretion, 117-118
- ADVERTISING**  
market trends for lower tar cigarettes, 202
- Age groups** See **DEMOGRAPHIC VARIABLES**
- AGRICULTURAL PRACTICES**  
(See also **GENETICS; TOBACCO CURING**)  
effect on cigarette smoke pharmacology, research recommendations, 55  
effect on smoke composition, 51
- ALCOHOL CONSUMPTION**  
interactive effect with smoking in etiology of upper digestive tract neoplasms, 42
- ALKALOID CONTENT**  
(See also **NICOTINE CONTENT**)  
in cigarette smoke, 97
- ALKALOIDS**  
(See also **NICOTINE**)  
carcinogenicity, 97
- AMINE CONTENT**  
in gas phase of cigarette smoke, 94
- ANGINA PECTORIS**  
role of carbon monoxide in exercise-induced angina, 46
- ANIMAL MODELS**  
(See also **BIOASSAY**)  
in assessment of health risks of lower tar and nicotine cigarettes, 14  
bladder neoplasms, 41  
cardiovascular effects of carbon monoxide, 46  
chronic obstructive lung disease, 43-44  
effect of maternal smoking on pregnancy, 167  
emphysema, 142  
esophageal neoplasms, 42-43  
laryngeal neoplasms, 41  
lung neoplasms, 34-40  
nicotine tolerance and physical dependence, 179  
nicotine use, 178-179  
oral neoplasms, 42  
pancreatic neoplasms, 42-43  
reduced carcinogenicity of cigarette smoke, 94  
smoking and cardiovascular diseases, 124  
sudden death due to cardiovascular disease, 44, 46  
tobacco-related diseases, research recommendations, 58  
transplacental carcinogenesis, 47
- ANTITRYPSIN**  
effect of cigarette smoke on activity, 137-138
- ANTITRYPSIN DEFICIENCY**  
in emphysema etiology, 137-138
- AROMATIC AMIDES**  
binding to nucleic acids, 91  
metabolic activation and carcinogenicity, 91
- AROMATIC AMINE CONTENT**  
in cigarette smoke, 97

## INDEX

- AROMATIC AMINE CONTENT**—Con.  
reduction of in cigarette smoke, 95
- AROMATIC AMINES**  
binding to nucleic acids, 91  
bladder neoplasms and, 94–95  
in bladder neoplasm etiology, 41  
metabolic activation and carcinogenicity, 91
- AROMATIC HYDROCARBON CONTENT**  
in tobacco smoke, 95–96
- AROMATIC HYDROCARBONS**  
“bay” region theory of carcinogenesis, 90  
carcinogenicity, 36–37, 93–95  
carcinogenicity of metabolic intermediates, 90  
cocarcinogenicity, 96  
health effects in fetus, research recommendations, 169
- ARYL HYDROCARBON HYDROXYLASE**  
effect of cigarette smoke on activity in microsomes, 47–48  
role in metabolic activation of aromatic hydrocarbons, 90
- ATHEROSCLEROSIS**  
role of cigarette tars, 119
- BEHAVIOR**  
effect of maternal smoking on children, 159
- BEHAVIOR, ANIMAL**  
self-administration of nicotine, 179
- BENZ(a)ANTHRACENES**  
carcinogenicity, 95  
in tobacco smoke, 95
- BENZOFLUORANTHENES**  
carcinogenicity, 95  
in tobacco smoke, 95
- BENZO(g,h,i)PERYLENE**  
cocarcinogenicity, 96  
in tobacco smoke, 96
- BENZO(c)PHENANTHRENE**  
carcinogenicity, 95  
in tobacco smoke, 95
- BENZO(a)PYRENE**  
carcinogenicity, 36–37, 95  
health effects in fetus, research recommendations, 169  
metabolic activation, 90
- BENZO(a)PYRENE CONTENT**  
in cigarettes (1955–1980), 85–86
- BENZO(a)PYRENE CONTENT**—Con.  
in tobacco smoke, 95
- BENZO(e)PYRENE**  
carcinogenicity, 95  
cocarcinogenicity, 96  
in tobacco smoke, 95–96
- BIOASSAY**  
(*See also* ANIMAL MODELS)  
in assessment of health risks of lower tar and nicotine cigarettes, 14  
cigarette smoke components, research recommendations, 53  
mouse skin assay for lung neoplasms, 34–35
- BIRTH WEIGHT**  
effect of lower tar and nicotine cigarettes, 159  
effect of maternal smoking, 158
- BLADDER NEOPLASMS**  
animal models, 41  
aromatic amines and, 41, 94–95  
carcinogens and mutagens in cigarette smoke, 41, 97
- BLOOD CHEMICAL ANALYSIS**  
recommendations for clinical testing facilities, 184
- BLOOD PLATELETS**  
effect of nicotine, 118
- BLOOD PRESSURE**  
effect of nicotine, 117
- BLOOD VESSELS**  
effect of nicotine, 117  
effect of tobacco antigens on endothelium, 119
- BREAST FEEDING**  
(*See also* LACTATION)  
recommended research on maternal smoking and, 166
- Bronchial epithelium** *See* TRACHEOBRONCHIAL EPITHELIUM
- BRONCHITIS**  
(*See also* CHRONIC OBSTRUCTIVE LUNG DISEASE)  
effect of filtered cigarettes on mortality risk, 140–141  
smoking and, 135–136
- CADMIUM**  
hypertension and, 119
- CADMIUM CONTENT**  
in cigarette smoke, 97

## INDEX

- Cancer** *See* **NEOPLASMS**
- CARBON MONOXIDE**  
(*See also* **CARBOXYHEMOGLOBIN**)  
animal models of cardiovascular effects, 46  
in cardiovascular disease etiology, 118  
in coronary heart disease etiology, 10  
effect on heart function, 118  
effect on myocardium, 118  
effect on pregnancy, 46-47  
exercise-induced angina and, 48  
health effects, research recommendations, 57  
health effects in fetus, research recommendations, 168-169
- CARBON MONOXIDE CONTENT**  
(*See also* **CARBOXYHEMOGLOBIN LEVELS**)  
in alveoli, effect of lower tar and nicotine cigarettes, 181  
correlation with tar yield, 209, 211  
factors influencing yield in mainstream smoke, 10  
in filtered vs. nonfiltered cigarettes, 96-97, 119-120  
reduction of in cigarettes, Public Health Service recommendations, 201
- CARBOXYHEMOGLOBIN**  
(*See also* **CARBON MONOXIDE**)  
in cardiovascular disease etiology, 118
- CARBOXYHEMOGLOBIN LEVELS**  
(*See also* **CARBON MONOXIDE CONTENT**)  
effect of lower tar and nicotine cigarettes, 181-182
- CARCINOGENESIS**  
(*See also* **MUTAGENESIS**)  
"bay" region theory, 90  
induced by lower tar and nicotine cigarettes, 88-89  
recommendations for research on lower tar and nicotine cigarettes, 99-101  
role of nicotine, 91-93  
role of smoke-induced microsomal oxidase activity, 48  
transplacental carcinogenesis, 98-99  
value of mutagenesis assays in prediction of, 42-43
- CARCINOGENESIS—Con.**  
value of sebaceous gland suppression assay in prediction of, 43
- CARCINOGENS**  
(*See also* **COCARCINOGENS; MUTAGENS**)  
benzo(a)pyrene, 36-37  
binding to proteins, 90-91  
formation and activation in vivo, 89-93  
in gas phase of cigarette smoke, 93-94  
lung carcinogens in cigarette smoke, 35-41  
maternal-fetal exchange of cigarette smoke components, 98-99  
metabolic activation by mixed function oxidase systems, 89  
nicotine, 39, 91-93  
nitrosamines, 37, 40  
organ-specific agents in particulate phase, 94, 97  
in particulate phase of tobacco smoke, 94-95  
polonium-210, 40  
polycyclic aromatic hydrocarbons, 36-37, 93-94  
prediction of activity by mutagenesis assay systems, 42-43  
prediction of activity by sebaceous gland suppression test, 43  
tobacco flavor additives, 99  
weak acids, 38
- CARDIOVASCULAR DISEASES**  
(*See also* **CORONARY DISEASE**)  
animal models of sudden death, 44, 46  
carbon monoxide in etiology of, 118  
effect of lower tar and nicotine cigarettes on risk, summary of findings, 19-20, 125-126  
effect of smoking on risk, 115-117  
research recommendations, 120-125
- CARDIOVASCULAR SYSTEM**  
(*See also* **HEART FUNCTION; HEART RATE**)  
effect of carbon monoxide, 46  
effect of lower nicotine cigarettes on function, 118  
effect of nicotine on function, 117-118
- CATECHOL CONTENT**  
in tobacco smoke, 96

## INDEX

- CATECHOLS**  
carcinogenicity, 38  
cocarcinogenicity, 38, 96
- CATECHOLAMINE LEVELS**  
effect of nicotine, 117-118
- CEREBROVASCULAR DISORDERS**  
(*See also* **CARDIOVASCULAR DISEASES**)  
effect of filtered cigarettes on mortality, 119
- CESSATION OF SMOKING**  
(*See also* **EX-SMOKERS; REDUCTION OF SMOKING**)  
effect on coronary heart disease risk, 115-116  
effect on neoplasm risk, 80  
males vs. females, 214  
recommended programs for pregnant women, 162-163  
recommended research on pregnancy and, 162-163  
relationship of tar and nicotine yield to cessation attempts, 223-228  
role of lower tar and nicotine cigarettes, 183, 223-228  
role of lower tar and nicotine cigarettes, summary of findings, 24, 229-230
- CHILDREN**  
(*See also* **NEONATE**)  
effect of maternal smoking on health, 158-159  
effect of maternal smoking on physical, intellectual, and emotional development, 159  
effect of maternal smoking, summary of findings, 21-22, 170  
effect of parental smoking on health, 158-159
- CHROMOSOMES**  
(*See also* **MUTAGENESIS**)  
aberrations in smokers vs. nonsmokers, 48
- CHRONIC OBSTRUCTIVE LUNG DISEASE**  
(*See also* **BRONCHITIS; EMPHYSEMA**)  
animal models, 43-44  
effect of lower tar cigarettes on risk, 11-12  
effect of lower tar and nicotine cigarettes on risk, summary of findings, 20-21, 148-149
- CHRONIC OBSTRUCTIVE LUNG DISEASE—Con.**  
lower tar and nicotine cigarettes in etiology of, research recommendations, 142-148  
smoking characteristics and, 139  
smoking in etiology of, 11-12, 135-136  
smoking in etiology of, summary of findings, 20-21, 148-149
- CHRYSENE**  
carcinogenicity, 95
- CHRYSENE CONTENT**  
in tobacco smoke, 95
- CIGARETTE PAPER**  
effect of porosity on smoke composition, 50
- Cigarette smoke** *See* **SMOKE, CIGARETTE**
- Cigarette smoke, gas phase** *See* **GAS PHASE, CIGARETTE SMOKE**
- Cigarette smoke, particulate phase** *See* **PARTICULATE PHASE, CIGARETTE SMOKE**
- Cigarette smoking** *See* **SMOKING**
- Cigarette tars** *See* **TARS, CIGARETTE**
- CIGARETTE VENTILATION**  
effect on smoke composition, 50
- CIGARETTES**  
benzo(a)pyrene content (1955-1980), 85-86  
consumption trends, 80  
correlation between carbon monoxide yield and tar yield, 209, 211  
correlation between nicotine yield and tobacco weight, 209-210  
correlation between tar yield and nicotine yield, 206, 208-210  
correlation between tar yield and tobacco weight, 209-210, 212  
development of optimum tar to nicotine ratios, 184-185  
effect of butt and overwrap lengths on tar and nicotine yields, 211  
effect of product design on smoke composition, 49-50  
federal regulation of, 6, 201  
monitoring smoke components in new products, 53  
nicotine yields of U.S. brands (1978-1979), 230-234  
recommendations for research cigarettes, 184-185

## INDEX

### **CIGARETTES—Con.**

- tar yields of U.S. brands (1978–1979), 230–234
- trends in daily consumption, 213–214
- trends in per capita consumption, 213–216

### **CIGARETTES, FILTERED**

(See also **FILTERS**)

- carbon monoxide content, 96–97
- effect on bronchitis mortality risk, 140–141
- effect on cardiovascular disease risk, summary of findings, 20, 126
- effect on cerebrovascular disorder mortality, 119
- effect on coronary heart disease morbidity and mortality, 119–120
- effect on cough prevalence, 140
- effect on laryngeal neoplasm risk, 83–84
- effect on lung neoplasm risk, 82–85
- nicotine yields of U.S. brands (1978–1979), 230–234
- nitrogen oxide content, 97
- recommendations for research cigarettes, 184
- tar yields of U.S. brands (1978–1979), 230–234
- use trends, 201

### **CIGARETTES, HIGH-NICOTINE**

- demographic characteristics of users, 219
- effect on pancreatic elastase levels in dogs, 44–45

### **CIGARETTES, HIGH-TAR**

- demographic characteristics of users, 217–218
- use trends in males vs. females, 217–219

### **CIGARETTES, LOWER TAR AND NICOTINE**

- assessment of relative health risks, 8–15
- behavioral and economic factors affecting use, 182
- carcinogenicity, 88–89
- carcinogenicity, summary of findings, 18–19, 101–102
- in chronic obstructive lung disease etiology, research recommendations, 142–148
- compensatory smoking behavior, 7–8, 52, 57, 86, 97–98, 119, 177, 180–182

### **CIGARETTES, LOWER TAR AND NICOTINE—Con.**

- determination of physical and chemical properties of smoke, research recommendations, 55–56
- development of research cigarettes, 58–59, 184–185
- effect on antitrypsin activity, 137–138
- effect on birthweight, 158
- effect on cardiovascular disease risk, research recommendations, 120–125
- effect on cardiovascular disease risk, summary of findings, 19–20, 125–126
- effect on chronic obstructive lung disease risk, 11–12
- effect on chronic obstructive lung disease risk, summary of findings, 20–21, 148–149
- effect on coronary heart disease mortality, 119–120
- effect on coronary heart disease risk, 9–11, 116–117
- effect on elastase activity, 137–138
- effect on lung function, research recommendations, 144–146
- effect on lung neoplasm morbidity and mortality rates, 79
- effect on lung neoplasm mortality risk, 81–85
- effect on mortality rate, 12–13
- effect on pregnancy, 12, 159
- effect on pregnancy and infant health, research recommendations, 160–162, 169–170
- effect on pregnancy and infant health, summary of findings, 21–22, 170
- effect on tracheobronchial epithelium, 87–88, 142
- market trends, 80, 199–212
- product choice and use, summary of findings, 22–24, 228–230
- recommendations for carcinogenesis research, 99–101
- research recommendations from the Working Meeting on Low-Yield Cigarettes (June 1980), 24–26
- role in cessation of smoking, summary of findings, 24, 229–230
- role in cessation or reduction of smoking, 183

## INDEX

- CIGARETTES, LOWER TAR AND NICOTINE**  
 role in initiation, maintenance, and cessation of smoking, summary of findings, 22, 186  
 role in initiation of smoking habit, 182-183  
 role in maintenance of smoking habit, 183  
 use in male vs. female adolescents, 183  
 use trends, 199-223
- CIGARETTES, LOW-NICOTINE**  
 compensatory smoking behavior, 177, 180-182  
 demographic characteristics of users, 219  
 effect on cardiovascular function, 118  
 compensatory smoking behavior, research recommendations, 57  
 role in cessation of smoking, 223-228  
 trends in sales-weighted average, 205-208  
 use trends, 177, 219-221
- CIGARETTES, LOW-TAR**  
 compensatory smoking behavior, 7-8, 177, 180-182  
 definition, 205  
 demographic characteristics of users, 217-218  
 effect of compensatory smoking on chronic obstructive lung disease risk, 140  
 effect on chronic obstructive lung disease risk, 11-12  
 effect on coronary heart disease risk, 9-11  
 effect on lung function, 139-140  
 effect on lung neoplasm risk, 9  
 effect on neoplasm risk, 80  
 effect on sputum production, 139-140  
 health effects of sidestream smoke, research recommendations, 56  
 market trends, 201-202, 205-206  
 role in cessation of smoking, 223-228  
 trends in sales-weighted average, 205-208  
 use trends in adolescents, 220-222  
 use trends in males vs. females, 217-221
- CIGARETTES, LOW-TAR—Con.**  
 yield of non-tar constituents, 7-8
- CIGARETTES, MEDIUM-NICOTINE**  
 recommendations for use, 98, 180  
 research recommendations, 58
- CIGARETTES, NON-NICOTINE**  
 attitudes of smokers, 177
- CIGARETTES, NONTOBACCO**  
 effect of nicotine content on product use, 177
- CILIARY ACTIVITY**  
*(See also PULMONARY CLEARANCE)*  
 determination of ciliotoxic smoke components, 57  
 effect of cigarette smoke, 47
- COCARCINOGENS**  
*(See also CARCINOGENS; MUTAGENS)*  
 catechol, 38  
 nicotine, 39-40, 94  
 in particulate phase of tobacco smoke, 94, 96  
 phenols, 38  
 weak acids, 38
- Compensatory smoking** *See SMOKING CHARACTERISTICS*
- CORONARY DISEASE**  
*(See also CARDIOVASCULAR DISEASES)*  
 carbon monoxide in etiology of, 10  
 effect of filtered cigarettes on morbidity and mortality, 119-120  
 effect of lower tar and nicotine cigarettes on mortality, 119-120  
 effect of lower tar and nicotine cigarettes on risk, 9-11, 116-117  
 effect of lower tar and nicotine cigarettes on risk, summary of findings, 19-20, 125-126  
 effect of lower tar cigarettes on risk, 9-11  
 effect of smoking on risk, 9-10, 115-117  
 Multiple Risk Factor Intervention Trial (MRFIT), 122  
 risk in ex-smokers, 115-116
- Coronary heart disease** *See CORONARY DISEASE*
- COUGH**  
*(See also RESPIRATORY SYMPTOMS)*  
 effect of filtered cigarettes on prevalence, 140

## INDEX

- CYANIDE CONTENT**  
in cigarette smoke, 94
- DEMOGRAPHIC VARIABLES**  
(See also **SEX RATIO**)  
high- vs. low-nicotine cigarette users, 219  
high- vs. low-tar cigarette users, 217-218  
mean daily dose of tar and nicotine in smokers by race, sex, and age, 219-220  
use of high- vs. low-tar cigarettes in smokers by educational level, 218  
use of high- vs. low-tar cigarettes in smokers by income level, 218
- DIBENZACRIDINES**  
carcinogenicity, 95  
in tobacco smoke, 95
- DIBENZ(a,h)ANTHRACENE**  
carcinogenicity, 95  
in tobacco smoke, 95
- DIBENZO(c,g)CARBAZOLE**  
carcinogenicity, 95  
in tobacco smoke, 95
- DIBENZOPYRENES**  
carcinogenicity, 95  
in tobacco smoke, 95
- Educational level** See **DEMOGRAPHIC VARIABLES**
- ELASTASE**  
effect of cigarette smoke on levels, 137-138  
effect of high-nicotine cigarette smoke on levels in dogs, 44-45  
role in emphysema etiology, 43-44, 137-138
- EMPHYSEMA**  
(See also **CHRONIC OBSTRUCTIVE LUNG DISEASE**)  
animal models, 142  
biochemical markers in early detection of, 139  
cigarette smoke in etiology of, 43-44  
etiology, 43-44, 137-138  
induced by smoke inhalation in animals, 43, 142  
nitrogen oxides in etiology of, 138-139  
smoking and, 135-136  
smoking in etiology of, 137-139
- Endothelium** See **BLOOD VESSELS**
- ENVIRONMENTAL POLLUTION**  
(See also **OCCUPATIONAL EXPOSURE**)  
interaction with smoking, research recommendations, 56-57
- ENZYME ACTIVITY**  
(See also **ARYL HYDROCARBON HYDROXYLASE; ELASTASE; OXIDASE ACTIVITY**)  
effect of cigarette smoke on elastase, 137-138  
effect of cigarette smoke on microsomal oxidases, 47-48  
effect of high-nicotine cigarette smoke on elastase levels in dogs, 44-45  
role in metabolic activation of carcinogens, 89  
role of elastase in emphysema etiology, 43-44, 137-138
- ESOPHAGEAL NEOPLASMS**  
animal models, 42-43  
carcinogens in particulate matter of cigarette smoke, 97  
induced by nitrosornicotine in rats, 41-42  
smoking and alcohol consumption in etiology of, 42
- EX-SMOKERS**  
(See also **CESSATION OF SMOKING**)  
coronary heart disease risk, 115-116
- FATTY ACIDS**  
effect of nicotine on levels in blood, 117
- FETAL MORTALITY**  
(See also **PERINATAL MORTALITY**)  
effect of maternal smoking, 158
- FETUS**  
effect of lower tar and nicotine cigarettes, 159  
effect of maternal smoking, 157-159  
effect of maternal smoking, research recommendations, 159-170
- Filtered cigarettes** See **CIGARETTES, FILTERED**
- FILTERS**  
(See also **CIGARETTES, FILTERED**)  
effect on carbon monoxide delivery, 119-120

## INDEX

- FILTERS**—Con.  
effect on smoke composition, 50  
perforated type, 97
- Forced expiratory volume** *See* **LUNG FUNCTION; RESPIRATORY FUNCTION TESTS**
- Forced vital capacity** *See* **LUNG FUNCTION; RESPIRATORY FUNCTION TESTS**
- GAS PHASE, CIGARETTE SMOKE**  
(*See also* **SMOKE, CIGARETTE**)  
carcinogens, 93–94  
toxic components, 33
- GENETICS**  
effect on cigarette smoke pharmacology, research recommendations, 55  
use in modification of cigarette smoke composition, 50
- HEALTH EDUCATION**  
public awareness of health hazards of smoking, 200–202
- HEART FUNCTION**  
effect of carbon monoxide, 118  
effect of nicotine, 117
- HEART RATE**  
effect of nicotine, 117
- HETEROCYCLIC NITROGEN COMPOUNDS**  
carcinogenicity, 97  
in cigarette smoke, 94, 97
- HUMECTANTS**  
(*See also* **TOBACCO ADDITIVES; TOBACCO FLAVOR**)  
in cigarettes, 51–52
- HYPERTENSION**  
cadmium and, 119
- IMMUNE SYSTEM**  
effect of smoking, 48
- INDOLES**  
cocarcinogenicity, 96  
in tobacco smoke, 96
- INFANT MORTALITY**  
(*See also* **PERINATAL MORTALITY**)  
effect of maternal smoking on sudden infant death syndrome risk, 158–159
- Infant, newborn (0-1 month)** *See* **NEONATE**
- Inhalation** *See* **SMOKING CHARACTERISTICS**
- INTELLECTUAL DEVELOPMENT**  
effect of maternal smoking on children, 159
- KIDNEY NEOPLASMS**  
carcinogens in particulate phase of cigarette smoke, 97
- LACTATION**  
(*See also* **BREAST FEEDING**)  
recommended research on maternal smoking and, 166
- LARYNGEAL NEOPLASMS**  
animal models, 41  
effect of filtered cigarettes on risk, 83–84  
induced by cigarette smoke inhalation in hamsters, 41  
induced by nitrosamines in hamsters, 41
- LEGISLATION**  
federal regulation of tobacco industry, 201
- Lower nicotine cigarettes** *See* **CIGARETTES, LOWER TAR AND NICOTINE; CIGARETTES, LOW-NICOTINE**
- Lower tar cigarettes** *See* **CIGARETTES, LOWER TAR AND NICOTINE; CIGARETTES, LOW-TAR**
- LUNG FUNCTION**  
(*See also* **PULMONARY CLEARANCE; RESPIRATORY FUNCTION TESTS**)  
effect of lower tar and nicotine cigarettes, research recommendations, 144–146  
effect of smoke inhalation in rats, 43  
effect of smoking, 138  
effect of tar yield, 139–140  
smokers vs. nonsmokers, 141
- LUNG NEOPLASMS**  
animal models, 34–40  
carcinogens in cigarette smoke, 35–41, 97  
cigarette tar in etiology of, 79  
effect of filtered cigarettes on risk, 82–85



## INDEX

- LUNG NEOPLASMS—Con.**  
effect of lower tar and nicotine cigarettes on morbidity and mortality rates, 79  
effect of lower tar and nicotine cigarettes on risk, summary of findings, 18–19, 101–102  
effect of lower tar cigarettes on risk, 9  
effect of smoking on risk, 9  
effect of tar and nicotine content on mortality risk, 81–85
- LUNGS**  
small airway pathology in smokers, 138
- MATERNAL-FETAL EXCHANGE**  
animal models of transplacental carcinogenesis, 47  
cigarette smoke carcinogens, 98–99  
*Maternal smoking* See **SMOKING**
- MATERNAL**  
**Maximum mid-expiratory flow measurements** See **LUNG FUNCTION; RESPIRATORY FUNCTION TESTS**
- Mixed function oxidases** See **OXIDASE ACTIVITY**
- MORBIDITY**  
dose-response relationship between smoking and disease, 6–8
- MORTALITY**  
(See also **FETAL MORTALITY; INFANT MORTALITY; PERINATAL MORTALITY**)  
cardiovascular diseases, effect of filtered cigarettes on risk, 119–120  
effect of lower tar and nicotine cigarettes, 12–13
- MUTAGENESIS**  
(See also **CARCINOGENESIS; CHROMOSOMES**)  
sister chromatid exchange in smokers vs. nonsmokers, 48  
value of assays in prediction of carcinogenic potential, 42–43
- MUTAGENS**  
(See also **CARCINOGENS; COCARCINOGENS**)  
in cigarette smoke, 37–38  
tobacco flavor additives, 99  
in urine in smokers vs. nonsmokers, 41
- MYOCARDIUM**  
effect of carbon monoxide, 118
- NAPHTHYLAMINE**  
in bladder neoplasm etiology, 41
- NEONATE**  
effect of maternal smoking, 158–159  
effect of maternal smoking, research recommendations, 159–170  
effect of maternal smoking, summary of findings, 21–22, 170
- NEOPLASMS**  
effect of cessation of smoking on risk, 80  
effect of lower tar and nicotine cigarettes on risk, summary of findings, 18–19, 101–102  
effect of lower tar cigarettes on risk, 80  
smoking in etiology of, 79–80
- NICKEL CONTENT**  
carcinogenicity, 97  
in cigarette smoke, 97
- NICOTINE**  
animal models of tolerance and physical dependence, 179  
animal models of nicotine use, 178–179  
cocarcinogenicity, 39–40, 94  
effect on blood platelets, 118  
effect on cardiovascular function, 117–118  
effect on catecholamine levels, 117  
effect on cortisol secretion, 117–118  
effect on fatty acid levels in blood, 117  
effect on pregnancy, 46–47  
evaluation of health effects, research recommendations, 54  
health effects in fetus and child, research recommendations, 168  
intravenous and oral exposure in smokers, 177–178  
role in carcinogenesis, 39, 91–93  
role in maintenance of smoking habit, 177–180, 183  
self-administration in animals, 179
- NICOTINE CONTENT**  
in blood, effect of lower tar and nicotine cigarettes, 181–182  
cessation of smoking attempts and, 223–228  
in cigarettes, development and validation of analytical methods, 56

- NICOTINE CONTENT—Con.**  
 cigarettes in the United States (1978–1979), 230–234  
 correlation with tar yield, 206, 208–210  
 correlation with tobacco weight per cigarette, 209–210  
 effect of puffing profile on yield, 210–211  
 effect of smoking characteristics on yield, 210–211  
 effect on daily cigarette consumption, 222–225  
 effect on lung neoplasm mortality risk, 81–85  
 mean daily dose in smokers by race, sex, and age, 219–220  
 percentage distribution of smokers by nicotine yield, 219, 221  
 relationship to nitrosamine content in tobacco smoke, 39
- NICOTINE REDUCTION**  
 Public Health Service recommendations, 200–201
- NITRATE CONTENT**  
 2-nitropropane in cigarette smoke, 94
- NITROGEN OXIDE CONTENT**  
 in cigarettes with perforated filter tips, 97
- NITROGEN OXIDES**  
 in emphysema etiology, 138–139
- NITROSAMINE CONTENT**  
 in cigarette smoke, 37, 94–95, 97  
 in tobacco, 37  
 reduction of in cigarette smoke, 40, 95–96  
 relationship to nicotine content in tobacco smoke, 39
- NITROSAMINES**  
 carcinogenicity, 37, 40, 91–92, 97  
 carcinogenicity in animals, 95–96  
 in esophageal neoplasm induction in rats, 41–42  
 formation in cigarette smoke, 40  
 formation in tobacco and tobacco smoke, 95  
 formation in vivo, 40, 92–93, 95–96  
 in laryngeal neoplasm induction in hamsters, 41  
 in pancreatic neoplasm induction in hamsters, 42
- NITROSOMETHYLUREA**  
 in neoplasm induction in animals, 92
- NUCLEIC ACIDS**  
 binding of aromatic amides and amines, 91
- Obstructive airway diseases** *See* **BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; EMPHYSEMA**
- OCCUPATIONAL EXPOSURE**  
 (*See also* **ENVIRONMENTAL POLLUTION**)  
 interaction with smoking, research recommendations, 56–57
- ORAL NEOPLASMS**  
 animal models, 42  
 smoking and alcohol consumption in etiology of, 42
- OXIDASE ACTIVITY**  
 effect of cigarette smoke on microsomal oxidases, 47–48  
 role in carcinogenesis, 48, 89
- PANCREATIC NEOPLASMS**  
 animal models, 42–43  
 carcinogens in particulate phase of cigarette smoke, 97  
 induced by diisopropyl nitrosamine in rats, 42
- Parental smoking** *See* **SMOKING, PARENTAL**
- PARTICULATE PHASE, CIGARETTE SMOKE**  
 (*See also* **SMOKE, CIGARETTE; SMOKE, TOBACCO; TARS, CIGARETTE**)  
 carcinogens, 94–95, 97  
 cocarcinogens, 94, 96  
 toxic components, 33–34
- PASSIVE SMOKING**  
 (*See also* **SMOKE STREAMS**)  
 health effects of lower tar and nicotine cigarettes, research recommendations, 56, 58  
 public attitudes toward health effects, 204
- Peak expiratory flow measurements**  
*See* **LUNG FUNCTION; RESPIRATORY FUNCTION TESTS**
- PERINATAL MORTALITY**  
 (*See also* **INFANT MORTALITY**)  
 effect of lower tar and nicotine cigarettes on risk, 159  
 effect of maternal smoking, 158  
 risk factors, 158

## INDEX

- PHENOLS**  
carcinogenicity, 38  
cocarcinogenicity, 38
- PLACENTA**  
effect of maternal smoking, 157-158  
effect of maternal smoking, research  
recommendations, 164-165
- POLONIUM-210**  
carcinogenicity, 40, 97  
formation in cigarette smoke, 40  
formation in tobacco, 40
- POLONIUM-210 CONTENT**  
in cigarette smoke, 97  
reduction of in tobacco, 40
- Polycyclic aromatic hydrocarbons** *See*  
**AROMATIC HYDROCARBONS**
- PREGNANCY**  
(*See also* **FETUS; NEONATE**)  
animal models of maternal smoking  
and, 167  
effect of lower tar and nicotine cig-  
arettes, 12, 159  
effect of lower tar and nicotine cig-  
arettes, research recommenda-  
tions, 160-162, 169-170  
effect of maternal smoking, 46-47,  
157-159  
effect of maternal smoking, sum-  
mary of findings, 21-22, 170  
effect of maternal smoking, research  
recommendations, 159-170  
perinatal projects, 161  
recommended research on smoking  
cessation and, 162-163
- PREMATURITY**  
effect of maternal smoking on risk,  
158
- PROTEINS**  
binding of carcinogens, 90-91  
**Puffing parameters** *See* **SMOKING**  
**CHARACTERISTICS**
- PULMONARY CLEARANCE**  
(*See also* **CILIARY ACTIVITY;**  
**LUNG FUNCTION**)  
effect of cigarette smoke, 47  
**Pulmonary function** *See* **LUNG FUNC-**  
**TION**
- Racial groups** *See* **DEMOGRAPHIC**  
**VARIABLES**
- REDUCTION OF SMOKING**  
(*See also* **CESSATION OF SMOK-**  
**ING**)
- REDUCTION OF SMOKING—Con.**  
role of lower tar and nicotine cigar-  
ettes, 183
- RESPIRATORY FUNCTION TESTS**  
(*See also* **LUNG FUNCTION**)  
in early detection of lung disease,  
43, 141
- RESPIRATORY SYMPTOMS**  
(*See also* **COUGH**)  
effect of tar yield, 139-140
- SEX RATIO**  
(*See also* **DEMOGRAPHIC VARIA-**  
**BLES**)  
cessation of smoking, 214  
smoking habit in the United States,  
211-214  
use trends for high- and low-tar  
cigarettes, 217-219  
use trends for lower tar cigarettes  
among adolescents, 222
- SMOKE, CIGARETTE**  
(*See also* **GAS PHASE, CIGAR-**  
**ETTE SMOKE; PARTICULATE**  
**PHASE, CIGARETTE SMOKE;**  
**SMOKE STREAMS; SMOKE,**  
**TOBACCO**)  
analysis of components, research re-  
commendations, 52-53  
animal models of reduced carcino-  
genicity, 94  
bioassays of selected components, re-  
search recommendations, 53  
in chronic obstructive lung disease  
etiology, 143-144  
determination of toxicity, research  
recommendations, 52-53  
development of analytical methods,  
56, 124  
effect of agricultural practices on  
composition, 51  
effect of cigarette design on compo-  
sition, 49-50  
effect of filters on composition, 50  
effect of tobacco additives on com-  
position and activity, 51-52  
effect of tobacco curing on compo-  
sition, 51  
effect of tobacco processing on com-  
position, 51  
effect of tobacco varieties on com-  
position, 50  
effect of ventilation on composition,  
50

**SMOKE, CIGARETTE—Con.**

- effect on ciliary activity, 47
- effect on pulmonary clearance, 47
- in emphysema etiology, 43-44
- formation of components, 33
- lung carcinogens, 35-41
- metabolism of carcinogenic components, 89-93
- monitoring components in new products, 53
- monitoring relative vs. absolute yields of components, 54-55
- mutagenic vs. carcinogenic components, 37-38
- pharmacology and toxicology, summary of findings, 16-18, 59-61
- yield of constituents in lower tar products, 7-8

**SMOKE INHALATION**

- in emphysema induction in rats, 43
- in laryngeal neoplasm induction in hamsters, 41

**SMOKE STREAMS**

(See also **SMOKE, CIGARETTE; SMOKE, TOBACCO**)

- health effects of sidestream smoke from lower tar and nicotine cigarettes, 56, 58

**SMOKE, TOBACCO**

- pharmacology and toxicology, summary of findings, 16-18, 59-61

**SMOKERS VS. EX-SMOKERS**

- attitudes toward health hazards of smoking, 203

**SMOKERS VS. NONSMOKERS**

- attitudes toward health effects of passive smoking, 204
- chromosomal aberrations, 48
- coronary heart disease risk, 115
- lung function, 141
- mutagens in urine, 41
- sister chromatid exchange, 48
- small airway pathology, 138
- tracheobronchial epithelium, 87-88

**SMOKING**

- (See also **SMOKE, CIGARETTE; SMOKE INHALATION; SMOKE, TOBACCO; SMOKING, MATERNAL; SMOKING, PARENTAL**)
- in chronic obstructive lung disease etiology, 135-136
  - effect on cardiovascular disease risk, 115-117

**SMOKING—Con.**

- effect on coronary heart disease risk, 115-117

**SMOKING AND HEALTH**

- dose-response relationship between smoking and morbidity, 6-8
- public attitudes toward health effects of smoking, 202-204
- public awareness of health effects of smoking, 200-202
- recommendations for clinical testing facilities for smokers, 184

**Smoking behavior See SMOKING CHARACTERISTICS****SMOKING CHARACTERISTICS**

- accuracy of smoking machines in reproduction of, 49, 180, 185
  - compensatory smoking behavior with lower tar and nicotine cigarettes, 7-8, 52, 57, 86, 97-98, 119, 177, 180-182
  - compensatory smoking behavior, summary of findings, 22, 186
  - effect of compensatory smoking behavior on obstructive airway disease risk, 140
  - effect on acute airway response to smoke inhalation, 139
  - effect on tar and nicotine yields, 210-211
  - effect on yield of cigarette smoke constituents, 49
  - research recommendations, 53-54
- SMOKING HABIT**
- age at onset by tar and nicotine yield, 221-223
  - behavioral aspects, summary of findings, 22, 186
  - effect of alternative modes of nicotine exposure, 177-178
  - effect of tar and nicotine yield on daily cigarette consumption, 222-225
  - males vs. females in the United States, 211-214
  - role of lower tar and nicotine cigarettes in initiation of, 182-183
  - role of lower tar and nicotine cigarettes in maintenance of, 183
  - role of nicotine in maintenance of, 177-180, 183
  - trends in daily cigarette consumption, 80, 213-214

## INDEX

### SMOKING HABIT—Con.

- trends in per capita cigarette and tobacco consumption, 213–216
- trends in use of lower tar and nicotine products, 199
- trends in use of lower tar and nicotine cigarettes, summary of findings, 22–24, 228–230

### SMOKING MACHINES

- accuracy in reproducing smoking behavior, 49, 180, 185
- design parameters, 48–49, 53
- monitoring relative vs. absolute yields of smoke components, 54–55
- recommendations for improvement, 185
- recommendations for maximum yield assays, 185

### SMOKING, MATERNAL

- behavioral studies of pregnant women, research recommendations, 162–163
- effect on birthweight, 158
- effect on fetal mortality, 158
- effect on health of offspring, 158–159
- effect on perinatal mortality, 158
- effect on physical, intellectual, and emotional development in children, 159
- effect on placenta, 157–158
- effect on pregnancy, 46–47, 157–159
- effect on pregnancy and infant health, research recommendations, 159–170
- effect on pregnancy and infant health, summary of findings, 21–22, 170
- effect on prematurity risk, 158
- effect on spontaneous abortion risk, 158
- effect on sudden infant death syndrome risk, 158–159

### SMOKING, PARENTAL

- effect on health of offspring, 158–159

### SMOKING SURVEYS

- attitudes toward health effects of smoking in smokers vs. ex-smokers, 203
- National Clearinghouse on Smoking and Health surveys, 203

### SMOKING SURVEYS—Con.

- National Health Interview Study (NHIS), 199–201
- public attitudes toward health effects of smoking, 202–204
- public awareness of health effects of smoking, 200–202
- Roper Survey on smoking and health, 204
- use of filtered cigarettes, 201

### Spirometric measurements *See* LUNG FUNCTION

### SPUTUM PRODUCTION

- effect of tar yield, 139–140

### TAR CONTENT

- cessation of smoking attempts and, 223–228
- cigarettes in the United States (1978–1979), 230–234
- correlation with carbon monoxide yield, 209, 211
- correlation with nicotine yield, 206, 208–210
- correlation with tobacco weight per cigarette, 209–210, 212
- development of analytical methods, 56, 124
- effect of puffing profile on yield, 210–211
- effect of smoking characteristics on yield, 210–211
- effect on daily cigarette consumption, 222–225
- effect on lung function, 139–140
- effect on lung neoplasm mortality risk, 81–85
- effect on respiratory symptoms, 139–140
- effect on sputum production, 139–140
- mean daily dose in smokers by race, sex, and age, 219–220
- percent distribution of smokers by tar yield, 219–222

### TAR REDUCTION

- effect on coronary heart disease risk, 9–11
- Public Health Service recommendations, 200–201

### TARS, CIGARETTE

- (*See also* PARTICULATE PHASE, CIGARETTE SMOKE)
- atherosclerosis and, 119

## INDEX

- TARS, CIGARETTE**—Con.  
in lung neoplasm etiology, 79
- TOBACCO ADDITIVES**  
(*See also* **HUMECTANTS; TOBACCO FLAVOR**)  
assessment of health risks, 6, 8  
carcinogenicity and mutagenicity of flavoring agents, 99  
effect on smoke composition, 51-52  
flavoring agents, 51-52  
humectants, 51-52
- TOBACCO ANTIGENS**  
effect on endothelium, 119
- TOBACCO CURING**  
(*See also* **AGRICULTURAL PRACTICES**)  
effect on cigarette smoke pharmacology, research recommendations, 55  
effect on smoke composition, 51
- TOBACCO FLAVOR**  
(*See also* **HUMECTANTS; TOBACCO ADDITIVES**)  
carcinogenicity and mutagenicity of additives, 99
- TOBACCO FLAVOR**—Con.  
flavoring agents in cigarettes, 51-52
- TOBACCO INDUSTRY**  
federal regulation of, 6, 201
- TOBACCO PROCESSING**  
effect on smoke composition, 51
- TOBACCO VARIETIES**  
smoke composition, 50
- TRACHEOBRONCHIAL EPITHELIUM**  
effect of lower tar and nicotine cigarettes, 87-88, 142  
effect of smoking, 87-88
- Tumor initiating agents** *See* **CARCINOGENS**
- Tumor promoting agents** *See* **COCARCINOGENS**
- URETHANES**  
content in cigarette smoke, 94
- VINYL CHLORIDE**  
content in cigarette smoke, 94  
metabolic activation, 93
- Vital capacity** *See* **LUNG FUNCTION**